The initial experience of using fraxiparin in extracorporeal detoxication in clinical cardiology

: Procedures, connected with extracorporal blood circulation--hemodialysis, hemosorption and plasmapheresis--were used in complex of treatment in 30 patients with various cardiovascular diseases. As an anticoagulant in 8 patients was used the preparation of low molecular heparine (Fraxiparine) produced by "Sanofi" (France) firm, and in 22-heparin, produced by "Polfa" (Poland). Ascertained advantages of Fraxiparine versus heparin were: possibility of single injection of preparation, the reducing of total dose magnitude, which is needed for one curative act conduction, lowering by 70% approximately the hemorrhagic complications rate.